| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.GASTRO.2005.03.020 |
| P698 | PubMed publication ID | 15887101 |
| P2093 | author name string | Bjarni Thjodleifsson | |
| Ingvar Bjarnason | |||
| Asgeir Theodors | |||
| Juan Gonzalez | |||
| Laurence Maiden | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathology | Q7208 |
| P304 | page(s) | 1172-1178 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy | |
| P478 | volume | 128 |
| Q95359420 | Q95359420 |
| Q34802314 | 4 years after withdrawal of rofecoxib: where do we stand today? |
| Q42292414 | A Curious Case of Intestinal Diaphragm Disease Unmasked by Perforation of a Duodenal Ulcer. |
| Q36035409 | A Rapid Screenable Assay for Compounds That Protect Against Intestinal Injury in Zebrafish Larva. |
| Q38974252 | A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury |
| Q89977470 | A Review of Zinc-L-Carnosine and Its Positive Effects on Oral Mucositis, Taste Disorders, and Gastrointestinal Disorders |
| Q79764708 | A blinded pilot comparison of capsule endoscopy and small bowel histology in unresponsive celiac disease |
| Q47893028 | A novel model for NSAID induced gastroenteropathy in rats. |
| Q85244116 | Activation of α7 nicotinic acetylcholine receptors ameliorates indomethacin-induced small intestinal ulceration in mice |
| Q35957739 | Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study |
| Q43247710 | Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety |
| Q28069820 | Anemia and iron deficiency in gastrointestinal and liver conditions |
| Q45402264 | Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients |
| Q38500945 | Assessment of mucosal healing in inflammatory bowel disease: review. |
| Q48108406 | Associations between drugs and small-bowel mucosal bleeding: Multicenter capsule-endoscopy study. |
| Q58094570 | Bactericidal/Permeability-Increasing Fold-Containing Family B Member 4 May Be Associated with NSAID-Induced Enteropathy |
| Q34827230 | Beneficial effect of an omega-6 PUFA-rich diet in non-steroidal anti-inflammatory drug-induced mucosal damage in the murine small intestine. |
| Q38723867 | Bradykinin stimulates protein kinase D-mediated colonic myofibroblast migration via cyclooxygenase-2 and heat shock protein 27. |
| Q34568178 | CT enteroclysis/enterography findings in drug-induced small-bowel damage |
| Q57623469 | Calprotectin in ankylosing spondylitis – frequently elevated in feces, but normal in serum |
| Q26765929 | Capsule Endoscopy for Ileitis with Potential Involvement of Other Sections of the Small Bowel |
| Q60054066 | Capsule Endoscopy in Refractory Diarrhea-Predominant Irritable Bowel Syndrome and Functional Abdominal Pain |
| Q37370014 | Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy |
| Q34597057 | Capsule endoscopy in non-steroidal anti-inflammatory drugs-enteropathy and miscellaneous, rare intestinal diseases |
| Q80190950 | Capsule endoscopy in the pediatric patient |
| Q38238750 | Capsule endoscopy: Present status and future expectation |
| Q41827943 | Cattle bile aggravates diclofenac sodium-induced small intestinal injury in mice |
| Q47133048 | Characteristics of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-Induced Small Bowel Injury Identified by Single-Balloon Endoscopy or Capsule Endoscopy. |
| Q39257736 | Clinical Review of Small-Bowel Endoscopic Imaging |
| Q38809387 | Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. |
| Q41003076 | Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome |
| Q53320293 | Comparison of Risk Factors Between Small Intestinal Ulcerative and Vascular Lesions in Occult Versus Overt Obscure Gastrointestinal Bleeding. |
| Q51724113 | Comparison of magnetic resonance imaging and video capsule enteroscopy in diagnosing small-bowel pathology: localization-dependent diagnostic yield. |
| Q36251799 | Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis |
| Q55071130 | Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. |
| Q36253681 | Could a swimming creature inform us on intestinal diseases? Lessons from zebrafish |
| Q33613034 | Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness |
| Q42705851 | Diclofenac toxicity in human intestine ex vivo is not related to the formation of intestinal metabolites |
| Q51037569 | Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis. |
| Q28085134 | Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives |
| Q36747550 | Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? |
| Q42174422 | Does capsule endoscopy have an added value in patients with perianal disease and a negative work up for Crohn's disease? |
| Q84090051 | Double-contrast barium enteroclysis as a patency tool for nonsteroidal anti-inflammatory drug-induced enteropathy |
| Q38743869 | Down-regulation of hepatic CYP3A1 expression in a rat model of indomethacin-induced small intestinal ulcers |
| Q28222352 | Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal |
| Q88846582 | Drug-induced gastrointestinal disorders |
| Q38221321 | Drug-induced gastrointestinal disorders |
| Q42381589 | Effect of long-term proton pump inhibitor therapy and healing effect of irsogladine on nonsteroidal anti-inflammatory drug-induced small-intestinal lesions in healthy volunteers |
| Q53610108 | Effect of oral diclofenac intake on faecal calprotectin. |
| Q87895340 | Eicosanoids in the gastrointestinal tract |
| Q36477478 | Elevated levels of faecal calprotectin in primary Sjögren's syndrome is common and associated with concomitant organic gastrointestinal disease |
| Q83477158 | Endoscopic and clinical features of gastric ulcers in Japanese patients with or without Helicobacter pylori infection who were using NSAIDs or low-dose aspirin |
| Q40729543 | Endoscopic diagnosis of small intestinal diseases. |
| Q38188487 | Environmental and NSAID-enteropathy: dysbiosis as a common factor |
| Q38159096 | European evidence based consensus for endoscopy in inflammatory bowel disease |
| Q42721853 | Evaluation of gastrointestinal injury and blood flow of small bowel during low-dose aspirin administration |
| Q45793502 | Evaluation of selective cyclooxygenase-2 inhibitor-induced small bowel injury: randomized cross-over study compared with loxoprofen in healthy subjects |
| Q38056172 | Evaluation of the intestinal toxicity and transport of xenobiotics utilizing precision-cut slices |
| Q38085064 | Evaluation of the small bowel in inflammatory bowel disease. |
| Q92086816 | Faecal Calprotectin |
| Q47947065 | Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy |
| Q30481876 | Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes |
| Q37689925 | Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis |
| Q41578341 | Fecal calprotectin in patients with suspected small bowel disease--a selection tool for small bowel capsule endoscopy? |
| Q27026351 | Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies |
| Q38060828 | Gastrointestinal safety of NSAIDs and over-the-counter analgesics |
| Q28482202 | Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence |
| Q36486032 | Glafenine-induced intestinal injury in zebrafish is ameliorated by μ-opioid signaling via enhancement of Atf6-dependent cellular stress responses |
| Q90177046 | Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention |
| Q38339456 | Iatrogenic pathology of the intestines. |
| Q59653412 | Imaging and Evaluating Method as Part of Endoscopical Diagnostic Approaches |
| Q35103596 | Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy |
| Q34403939 | Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study |
| Q57116087 | Indomethacin-induced small intestinal injury is ameliorated by cilostazol, a specific PDE-3 inhibitor |
| Q36594979 | Inflammatory diseases modelling in zebrafish. |
| Q42318868 | Influence of Adrenalectomy on Protective Effects of Urocortin I, a Corticotropin-Releasing Factor, Against Indomethacin-Induced Enteropathy in Rats |
| Q46478383 | Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters |
| Q30481799 | Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction |
| Q30831076 | Initial Experience of Video Capsule Endoscopy After Intestinal Transplantation |
| Q43196969 | Initial Steps to Prevent Nonsteroidal Anti-Inflammatory Drug- or Aspirin-Induced Enteropathy: Long-Term Outcome Data |
| Q36658981 | Intestinal epithelial cell-derived μ-opioid signaling protects against ischemia reperfusion injury through PI3K signaling |
| Q64261314 | Involvement of gliadin, a component of wheat gluten, in increased intestinal permeability leading to non-steroidal anti-inflammatory drug-induced small-intestinal damage |
| Q28210493 | Iron status and the use of non-steroidal anti-inflammatory drugs in hemodialysis patients |
| Q40791146 | Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? |
| Q34565398 | Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? |
| Q51741758 | Isolated terminal ileal ulcerations in asymptomatic individuals: natural course and clinical significance |
| Q38443552 | Learning curve of capsule endoscopy |
| Q50210221 | Mechanisms of NLRP3 inflammasome activation and its role in NSAID-induced enteropathy |
| Q38097424 | Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy |
| Q57124260 | Minimally invasive surgery for obscure idiopathic ileal varices diagnosed by capsule endoscopy and double balloon endoscopy: report of a case |
| Q42015382 | Mitochondrial disorders in NSAIDs-induced small bowel injury |
| Q34067974 | Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury |
| Q35540435 | NSAID enteropathy and bacteria: a complicated relationship. |
| Q38350128 | NSAID enteropathy: appearance at CT and MR enterography in the age of multi-modality imaging and treatment. |
| Q38033092 | NSAID enteropathy: could probiotics prevent it? |
| Q37882741 | NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies |
| Q34670838 | NSAID-induced deleterious effects on the proximal and mid small bowel in seronegative spondyloarthropathy patients |
| Q43274525 | NSAIDs and the gastrointestinal tract |
| Q22242051 | New diagnostic imaging tools for inflammatory bowel disease |
| Q38974245 | Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease |
| Q42244383 | Non-steroidal anti-inflammatory drug-induced enteropathy |
| Q45400230 | Non-steroidal anti-inflammatory drug-induced enteropathy. |
| Q97551831 | Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective |
| Q37800668 | Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and Prevention |
| Q57131358 | Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease |
| Q36993530 | Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury |
| Q28200864 | Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice |
| Q34387174 | Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage |
| Q57072074 | Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice |
| Q90042392 | Objective evaluation for treat to target in Crohn's disease |
| Q81445235 | Occult GI bleeding in NSAID users--the base of the iceberg! |
| Q37721159 | Occult and obscure gastrointestinal bleeding: causes and clinical management |
| Q53493512 | Occult vs. overt upper gastrointestinal bleeding - inverse relationship and the use of mucosal damaging and protective drugs. |
| Q38510615 | Orengedokuto and berberine improve indomethacin-induced small intestinal injury via adenosine |
| Q59800501 | Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention |
| Q34301480 | Peyer's patches and mesenteric lymph nodes cooperatively promote enteropathy in a mouse model of food allergy. |
| Q46819055 | Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria |
| Q38691889 | Precision-cut intestinal slices: alternative model for drug transport, metabolism, and toxicology research |
| Q31027618 | Preliminary data on the use of apheresis in inflammatory bowel disease |
| Q34990032 | Present status and strategy of NSAIDs-induced small bowel injury |
| Q50205410 | Pretreatment with indomethacin results in increased heat stroke severity during recovery in a rodent model of heat stroke. |
| Q46682965 | Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study |
| Q41115536 | Preventative Effects of Sodium Alginate on Indomethacin-induced Small-intestinal Injury in Mice |
| Q43010967 | Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury |
| Q47691269 | Preventive effect of agaro-oligosaccharides on non-steroidal anti-inflammatory drug-induced small intestinal injury in mice. |
| Q39826904 | Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid |
| Q40096378 | Proton pump inhibitor therapy did not increase the prevalence of small-bowel injury: A propensity-matched analysis. |
| Q86631113 | Proton pump inhibitors are not the key for therapying non-steroidal anti-inflammatory drugs-induced small intestinal injury |
| Q43227958 | Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage |
| Q36040552 | Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial |
| Q85161214 | Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy |
| Q38155495 | Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges |
| Q38260626 | Recent developments in chimeric NSAIDs as safer anti-inflammatory agents. |
| Q57122623 | Reduced small-intestinal injury induced by indomethacin in interleukin-17A-deficient mice |
| Q39354761 | Review article: a practical approach to the clinical management of NSAID enteropathy |
| Q36589396 | Review article: capsule endoscopy - are all small intestinal lesions Crohn's disease? |
| Q41610302 | Risk factors for small bowel bleeding in chronic nonsteroidal anti-inflammatory drug users |
| Q38707937 | Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease |
| Q43638429 | Role of phospholipids in protection of the GI mucosa |
| Q45262131 | Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users |
| Q30629677 | Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks |
| Q84010735 | Serious upper gastrointestinal complications of NSAIDs and COX-2 selective agents |
| Q46526856 | Severe injury to the small bowel associated with a short course of diclofenac |
| Q89089670 | Sex differences in NSAID-induced perturbation of human intestinal barrier function and microbiota |
| Q57099329 | Small Bowel Lesions Mimicking Crohn's Disease |
| Q92711786 | Small Intestine Protection of Mica Against Non-Steroidal Anti-Inflammatory Drugs-Injury Through ERK1/2 Signal Pathway in Rats |
| Q38327887 | Small bowel capsule endoscopy: Where are we after almost 15 years of use? |
| Q38287025 | Small bowel injury in low-dose aspirin users |
| Q82963897 | Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam |
| Q41967700 | Small bowel ulcerative lesions are common in elderly NSAIDs users with peptic ulcer bleeding |
| Q42459374 | Small-Bowel Capsule Endoscopy in Patients with Suspected Crohn's Disease—Diagnostic Value and Complications |
| Q34255548 | Small-bowel mucosal injuries in low-dose aspirin users with obscure gastrointestinal bleeding. |
| Q42152120 | Sodium alginate ameliorates indomethacin-induced gastrointestinal mucosal injury via inhibiting translocation in rats |
| Q47446945 | Soluble Dietary Fiber Can Protect the Gastrointestinal Mucosa Against Nonsteroidal Anti-Inflammatory Drugs in Mice |
| Q48126426 | Soluble Dietary Fibers Can Protect the Small Intestinal Mucosa Without Affecting the Anti-inflammatory Effect of Indomethacin in Adjuvant-Induced Arthritis Rats |
| Q84198917 | Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats |
| Q38710551 | Suppression of calpain expression by NSAIDs is associated with inhibition of cell migration in rat duodenum |
| Q35573362 | Suppression of contractile activity in the small intestine by indomethacin and omeprazole |
| Q57121193 | Suppression of indomethacin-induced apoptosis in the small intestine due to Bach1 deficiency |
| Q36570803 | Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs |
| Q37835286 | Targets of chymase inhibitors |
| Q36411113 | Technology Insight: current status of video capsule endoscopy. |
| Q51311916 | Terminal-restriction fragment length polymorphism (T-RFLP) analysis for changes in the gut microbiota profiles of indomethacin- and rebamipide-treated mice. |
| Q38178603 | The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium. |
| Q38171862 | The use of fecal calprotectin as a biomarker in gastrointestinal disease |
| Q37338955 | Uncovering the uncertainty: Risk factors and clinical relevance of P1 lesions on small bowel capsule endoscopy of anemic patients. |
| Q42943660 | Undisclosed Use of Nonsteroidal Anti-Inflammatory Drugs May Underlie Small-Bowel Injury Observed by Capsule Endoscopy |
| Q57468646 | Using human iPS cell-derived enterocytes as novel in vitro model for the evaluation of human intestinal mucosal damage |
| Q34122878 | Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study |
| Q50590194 | Wireless capsule endoscopy in enteropathy induced by nonsteroidal anti-inflammatory drugs in pigs. |
| Q22305488 | Wireless capsule endoscopy: perspectives beyond gastrointestinal bleeding |
Search more.